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Abstract: Pulmonary hypertension (PH) is a disorder that develops as a result of remodeling of the pulmo-
nary vasculature and is characterized by narrowing/obliteration of small pulmonary arteries, leading to
increased mean pulmonary artery pressure and pulmonary vascular resistance. Subsequently, PH increases
the right ventricular afterload, which leads to right ventricular hypertrophy and eventually right ventricular
failure. The pathophysiology of PH is not fully elucidated, and current treatments have only a modest
impact on patient survival and quality of life. Thus, there is an urgent need for improved treatments or a
cure. The use of animal models has contributed extensively to the current understanding of PH pathophysi-
ology and the investigation of experimental treatments. However, PH in current animal models may not
fully represent current clinical observations. For example, PH in animal models appears to be curable with
many therapeutic interventions, and the severity of PH in animal models is also believed to correlate poorly
with that observed in humans. In this review, we discuss a variety of animal models in PH research, some
of their contributions to the field, their shortcomings, and how these have been addressed. We highlight the
fact that the constant development and evolution of animal models will help us to more closely model the
severity and heterogeneity of PH observed in humans.
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INTRODUCTION
Though often referred to as a disease, pulmonary hyper-
tension (PH) is probably most accurately described as a
pathophysiological parameter defined by certain hemody-
namic measurements, including pulmonary arterial sys-
tolic pressure greater than 35 mmHg, mean pulmonary
arterial pressure (mPAP) greater than 25 mmHg at rest
or 30 mmHg with exercise, pulmonary capillary wedge
pressure less than 15 mmHg, and a pulmonary vascular
resistance greater than 3 Wood units.1,2 PH leads to an
increase in right ventricular (RV) afterload and hypertro-
phic remodeling that eventually causes RV failure.3,4
PH is associated with infectious diseases, such as hu-
man immunodeficiency virus/acquired immune deficiency
syndrome (HIV/AIDS), schistosomiasis, and viral hepatitis,
as well as chronic noncommunicable conditions such as
sickle cell disease, systemic sclerosis, congenital heart de-
fects, and chronic obstructive pulmonary disease.2 It is
heterogeneous because of its etiology, gender differences
(in response to treatment), epidemiology, and variations
in mortality/survival rates.5-7 PH remains a deadly disease
with a 3-year mortality rate between 20% (in PH associ-
ated with congenital heart disease) and 80% (in PH associ-
ated with HIV or connective-tissue disease).8
Despite significant advancement in the management
of PH in the past 12 years, it remains without cure, which
is a major concern because it affects a significant part of
the population.9-16 Unfortunately, current treatments im-
prove PH only to a certain extent and do not afford per-
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manent reversal of pulmonary vascular remodeling or re-
duction of mPAP.9-16 The absence of a cure and the lim-
ited success of current PH treatment are mainly due to
the fact that the pathophysiology of PH is poorly under-
stood. Animal models aid in the understanding of the
disease pathophysiology because they provide the ideal plat-
form to investigate the pathophysiological processes that
underlie the disease progression. Animal models are also
useful for testing novel experimental treatments.
There are several animal models available to study PH
(see Table 1). We describe these animal models as single-
pathological-insult (SPI) models, multiple-pathological-
insult (MPI) models, knockout models, and overexpres-
sion models. In SPI models, PH is induced by a single
pathological insult, such as monocrotaline or chronic hyp-
oxia. In MPI models, multiple insults are combined, such
as chronic hypoxia and SU5416, in order to induce severe
PH. Concerns were raised that SPI models do not com-
pletely display the severity of PH observed in humans with
respect to histological and/or hemodynamic parameters.
However, we would like to suggest the possibility that PH
in humans may already be late in the disease progression
and that to compare this to the severity of PH observed in
animal models is incorrect. Although animal models do
not fully recapitulate the severity of full-blown human PH,
they may very well correlate with milder forms of human
PH, a stage that is often missed at the time of diagnosis.17
Nevertheless, animal models have undergone major devel-
opments and improvements over the years, and MPI mod-
els appear to correlate better with PH in humans. In this
review, we discuss the roles of various animal models in
PH research, describing how they have contributed to the
Table 1. Overview of various animal models in pulmonary hypertension (PH)
Various models Species Usage Dana Point (2008)
Single-pathological-insult (SPI) models
Monocrotaline (MCT) Rats Very common Group 1
Chronic hypoxia Rats/mice Very common Group 3
Schistosomiasis/Schistosoma chartarum Mice Common Group 1
Fawn-hooded rats Rats Uncommon Group 3
Pulmonary arterial banding Rats/mice Common Group 2
Multiple-pathological-insult (MPI) models
MCT + pneumonectomy Rats Uncommon Group 1
MCT + chronic hypoxia Rats Uncommon Group 3
Chronic hypoxia + SU5416 Rats Common Group 1/3
Knockout models
BMPR-2 Mice Uncommon Group 1
Vasoactive intestinal peptide Mice Uncommon No defined group
Endothelin receptor-B Mice Common No defined group
Apolipoprotein-E Mice Uncommon No defined group
Neprilysin Mice Uncommon No defined group
Overexpression models
Interleukin-6 Mice Uncommon No defined group
Angiopoeitin-1 Rats Common No defined group
Serotonin/5-HTT Mice Common No defined group
S100A4/Mts-1 Mice Uncommon No defined group
Note: We generated a table from a Medline/PubMed search for which we entered the names of all existing animal models
published in the past 15 years (1996–2012). A model was considered very common when at least 100 publications used it, common
when 30–99 publications did so, and uncommon when fewer than 30 publications did so. These reviewed publications included
research articles, editorials/expert opinions, and review articles. There were cases where the first article on a particular animal
model was published only after 1996; these publications were still included. SU5416: a vascular endothelial growth factor receptor-2
inhibitor that causes endothelial cell proliferation; BMPR-2: bone morphogenetic protein receptor-2; 5-HTT: 5-hydroxytryptamine
transporter; S100A4/Mts-1: a metastasis-promoting protein implicated in PH vascular remodeling.
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current understanding of the pathogenesis of PH and how
they evolved over time. We also highlight the importance
of MPI models as an improvement on SPI models of PH,
and we comment on the future of translational research in
the field of pulmonary vascular disease.
THE ANIMAL MODELS USED IN PH RESEARCH
Monocrotaline model
Monocrotaline (MCT) is an alkaloid from the plant
Crotalaria spectabilis and a constituent of an herbal tea used
by natives in the West Indies many years ago, and it is
known for its ability to cause hepatotoxicity and PH.18,19 In
1967, a model of PH was established by feeding rats the
seeds of C. spectabilis or by injecting nonhuman primates
with a suspension of MCT.20-23 It is now general practice
to induce PH in rats with a single subcutaneous/intra-
peritoneal injection of MCT (60–80 mg/kg).24 The mecha-
nism whereby MCT causes PH includes metabolism of
MCT in the liver by the enzyme cytochrome-P450 into pyr-
rolic derivatives that initiate endothelial injury in the pul-
monary vasculature.25 The endothelial injury is the initial
trigger for pulmonary vasculitis and obstructive pulmo-
nary vascular remodeling, characterized by narrowing/
obliteration of the vascular lumen. Histological investiga-
tion of the pulmonary vasculature in PH shows features
such as intimal hyperplasia, medial hypertrophy, and ad-
ventitial thickening (see Table 2).26,27 PH in the MCT
model is also characterized by increased apoptosis of en-
dothelial cells, proliferation of pulmonary arterial smooth
muscle cells (PASMCs), and resistance of PASMCs to apo-
ptosis.21-25
The MCT model is commonly used by researchers, is
reproducible and inexpensive, and does not require meticu-
lous technical skills.24 Therefore, one of the greatest ben-
efits of this model is that it has helped us to understand the
pulmonary vascular remodeling process and its pathophysi-
ology. This was mostly shown by studies that explored the
role of a genetic mutation in genes that are responsible for
the regulation of endothelial cell and PASMC apoptosis
and proliferation. Researchers discovered a mutation in the
gene that encodes for bone morphogenetic protein receptor-
2 (BMPR-2) and forms part of the transforming growth
factor superfamily of proteins.28-31 Normally, transforming
growth factor-β (TGF-β) signaling is initiated by signals
transmitted from smad (small mothers against decapen-
taplegia) molecules and binding of TGF-β ligands to the
TGF-β receptor.32-34 Subsequently, smad 2,3 or smad 1, 5,
and 8 are phosphorylated and collocalize with smad 4,
which translocates to the nucleus, where it modulates tran-
scription of target genes (see Fig. 1). Furthermore, with
the use of the MCT model, the TGF-β receptor, activin-A
receptor-like kinase-1, and expression of smad 3,4 were
shown to be reduced in the lungs of MCT-treated rats. This
was associated with a decrease in the expression of the full
BMPR-2 protein in the lungs of MCT rats, suggesting that
TGF-smad and BMPR-2 signaling is impaired in MCT-
induced PH, a characteristic shared with human PH.32-34
Other studies done in the MCT model also highlighted
the pivotal role of inflammatory cells (macrophages, den-
dritic cells, and mast cells) and cytokines (interleukin-6,
interleukin-1) in the early stages of pulmonary vascular re-
modeling observed in PH.35-37 Macrophages and dendritic
cells, both antigen-presenting cells, are believed to facilitate
the inflammatory response in PH, thereby contributing to
pulmonary vascular remodeling.38-40 Mast cells are special-
ized myeloid hematopoietic cells that are proposed to have
direct vasoactive effects and to stimulate remodeling by in-
creased production of matrix metalloproteinases.38-40 The
exact role of these inflammatory cells in PH is not fully
elucidated.38-40 A very attractive concept in the develop-
ment of therapeutic treatments is the use of gene and cell
therapy, which is now also considered in PH.41,42 The
Table 2. Broad overview of the main histological features of pulmonary hypertension (PH) within the different groups of human PH
PH group (Dana Point 2008) Main histological features
Group 1 Intimal hyperplasia, medial hypertrophy, plexiform lesions, angiomatoid lesions, fibrinoid necrosis
Group 2 Medial hypertrophy, adventitial thickening, hemosiderosis, interstitial edema and fibrosis
Group 3 Medial hypertrophy, muscularization of arterioles, eccentric intimal fibrosis of arteries, features
of vasculopathy
Group 4 Eccentric intimal fibrosis, recannulized thrombi, dilated, optically empty blood vessels
Group 5 Congestive vasculopathy, postthrombotic vasculopathy
Note: Adapted from Stenmark et al.26 and Ryan et al.27 This table provides a very broad overview of all of the main histological
features characteristic of a particular group of human PH.
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principle of gene therapy is that genes that are either not
expressed or overexpressed are therapeutically stimulated
or inhibited.41,42 This has been tested in the MCT model
and is of particular interest because many genes are differ-
entially expressed in PH.43-46 Hamidi et al.47 showed that
administration of the vasoactive intestinal peptide gene
significantly reversed and completely prevented MCT-
induced PH. Similar success has been achieved with ther-
apy that modulates the expression of the angiopoietin-1,
superoxide dismutase, and interleukin-1 genes.37,48,49 Cell
therapy, in particular stem cell therapy, is also useful in
PH because this may restore or replace damaged cells in
the pulmonary vasculature.50-52 Various methods of ad-
ministering exogenous cells have been investigated, includ-
ing intravenous, intratracheal, and direct implantation into
the lung.50-52 Cell therapy using mesenchymal stem cells is
considered as a treatment for PH because of the potential of
these cells to differentiate into other cell types and to secrete
paracrine factors that may initiate tissue repair.52 The MCT
model was also used to test mesenchymal stem cell therapy;
the result was significant improvement of RV function.52
One major shortcoming of the MCT model is that
most experimental treatments seem to improve, reverse,
and prevent pulmonary vascular damage and PH. Experi-
mental treatments that have been tested in this model
include serine elastase inhibition (M249314 or ZD0892),
platelet-derived growth factor inhibition (imatinib), Rho-
kinase inhibition (fasudil), endothelin receptor antago-
nists (endothelin-1), serotonin transporter inhibition (flu-
oxetine), phosphodiesterase-5 inhibition (sildenafil and
phosphodiesterase-3/4 inhibitors such as pumafentrine),
statins (simvastatin, pravastatin, and rosuvastatin), and
many others.53-64 The excessive degree of improvement
with these experimental treatments has been criticized in
the literature because it is believed to reflect imperfect
models, inadequate duration of the studies, and end-
points that do not correlate with the progression of PH
observed in humans.26,27 Gomez-Arroyo et al.24 suggest
that the MCT model harbors an MCT syndrome con-
sisting of pulmonary interstitial edema, myocarditis, and
hepatic veno-oclusive disease that is uncharacteristic of
severe human PH.24 Furthermore, in the MCT model, va-
soconstriction seems to be an important mechanism,
whereas this is found only in a subset of PH patients.24 It
is clear that the MCT model does not truly mimic severe
PH as observed in humans.24 This issue is partially ad-
dressed by MPI animal models in which PH is induced
by combining pathological insults.24 One such example
is when PH is induced by combining MCT with con-
tralateral pneumonectomy.64 As opposed to SPI models,
MPI models display features of severe PH, such as exces-
sive RV hypertrophy (RVH) and increased hemodynamic
measurements (such as mPAP and RV diastolic and sys-
tolic pressures).64 Furthermore, in the MCT model, the
disease progression toward death might be too short for
compensatory mechanisms to develop, and this has been
addressed by reducing the dose of MCT (30 mg/kg) that
causes compensated RVH.46 Studies like these show that
the MCT model has undergone important evolutionary
developments that has definitely allowed it to better model
PH observed in humans.
Chronic hypoxia model
In the early 1970s, researchers initiated experiments that
showed that chronic hypoxia (CHP) leads to PH in sev-
eral animals.65 CHP is observed in chronic obstructive pul-
monary disease, interstitial lung disease, sleep apnea, and
exposure to high altitudes and is thought to play a crucial
role in the development of PH.65,66 The CHP model is
assumed to be representative of group 3 (PH secondary to
lung disease and/or hypoxia) in the Dana Point classifica-
tion.26,27 In a typical model of CHP, rats are placed in a
hypobaric chamber (10% FiO2 for 3–4 weeks or hypobaric
Figure 1. TGF-β/BMPR-2 signaling axis in pulmonary hyper-
tension (PH): a simplified schematic diagram of the TGF-β and
BMPR-2 signaling pathways that underlie the pathogenesis of
PH. TGF-β and BMPR-2 bind to their receptors, where TGF-β
activates smad 2,3 and BMPR-2 activates smad 1,5,8. Upon
phosphorylation of these smad molecules, the smad 4 molecule
is activated by both pathways and translocates to the nucleus,
where it promotes transcription of target genes involved in cell
growth, proliferation, and apoptosis. BMPR-2: bone morphoge-
netic protein receptor-2; TGF-β: transforming growth factor-β;
smad: small mothers against decapentaplegia. Adapted from
Santibañez et al.186
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pressure of 380 mmHg, which is equivalent to half that at
sea level).66-70 A number of experimental treatments have
been shown to attenuate PH in this model, including di-
goxin, A-17 (an inhibitor of microRNA-17), hypercapnia at
a CO2 saturation of 6.5% combined with CHP (10% FiO2),
bosentan, dichloroacetate, and targeted gene delivery of
BMPR-2.43,55,67,70-72
The CHP model has greatly contributed to our current
understanding of the molecular processes involved in the
vascular remodeling induced by chronic pulmonary dis-
ease and oxygen deprivation.65-72 In the CHP model, it was
recently shown that there is an impairment of the signal-
ing pathway that induces vasodilatation, irrespective of an
increase in inducible nitric oxide synthase expression.71-74
This is believed to contribute to CHP-induced PH and
may have major implications for PH associated with
chronic obstructive pulmonary disease. This model re-
mains relevant but, as is the case with most animal
models, it is questioned whether CHP really models hu-
man PH.75-78
A shortcoming of the CHP model is that it does not
fully recapitulate the pulmonary vascular damage ob-
served in humans with PH.76-78 Furthermore, the CHP
model does not display obstructive intimal lesions in the
peripheral pulmonary arteries.76-78 CHP is used to induce
PH, but it rarely results in PH of the same severity ob-
served in humans, and the model should, therefore, be
further developed.76-78 In an attempt to improve this model,
Morimatsu et al.79 combined CHP with MCT. Rats were
first intraperitoneally injected with MCT (60 mg/kg) and
then exposed to hypobaric hypoxia at 380 mmHg for
3 weeks. Rats developed PH and RVH with concentric
neointimal thickening, abnormal endothelial cell prolifera-
tion, plexiform lesions, and vascular occlusion with fibrin
thrombi.79 These histological features are similar to those
seen in the lungs of patients with PH. So this improvement
of the model seems to be successful in displaying severe PH
with associated histological features. The reproducibility of
PH by CHP is inconsistent across animal strains.80-82 When
neonatal calves are exposed to CHP, they develop severe PH,
with mPAPs that approach systemic level and vascular re-
modeling that is much more severe than that in rats or
mice.83-89 Furthermore, in hamsters, CHP causes less
muscularization of the precapillary arteries than in rats.89
The extent of vascular remodeling in response to CHP
seems to be genetically determined, and genes such as HIF-
1α, eNOS, complement-3 (a component of innate immu-
nity), and BMPR-2 appear to play an instrumental role.81,90-97
The mouse model of CHP has helped to achieve great
insights into the vascular remodeling in PH with regard to
the role of growth factors, reactive oxygen species, and the
nitric oxide pathway.98-104 Mice exposed to CHP develop
increased mPAP but minimal pulmonary vascular remod-
eling, compared to rats.80-84 This limits the use of wild-type
mouse models that exhibit severe vascular lesions similar
to human PH. However, this limitation was addressed by
creating a mouse model of severe PH by combining CHP
and SU-5416, an inhibitor of the vascular endothelial
growth factor (VEGF) receptor-2.102-106 SU-5416 inhibits
VEGFR-2, which plays a prosurvival role in endothelial
cells and leads to endothelial apoptosis that contributes
to the development of PH.102-106 Constant improvement
of the model appears to bring us one step closer to better
modeling and understanding of the full complexity of PH.
CHP combined with SU-5416
In 2011, Ciuclan et al.105 developed this mouse model of
severe PH by injecting mice weekly with SU-5416
(20 mg/kg) and then exposing them to CHP (10% FiO2)
for 7, 14, or 21 days. This is different from the protocol
for rats, during which they receive a single injection of
SU-5416 (20 mg/kg) and are then exposed to CHP (10%
FiO2) for 3 weeks.
105 This fairly new development of the
CHP model allows researchers to study the angioprolifera-
tive features of PH, in addition to hemodynamic changes.
In rats, CHP+SU-5416 causes PH with pulmonary arterial
changes resembling plexiform lesions that are virtually un-
responsive to treatments such as iloprost and C-type natri-
uretic peptide.107,108 This model displays increased RVH
and RV systolic pressure.105-108 Although some may view
this as negative results (i.e., failing to attenuate PH), it does
indicate that the experimental PH correlates well with the
unresponsiveness of PH to some treatments in humans.
The unresponsiveness to treatment and irreversibility of
PH are important features of this model and may mean
that the model relates more closely to human PH. This
improvement of the CHP model will add greater clinical
relevance to data generated fromMPImodels.
Fawn-hooded rat model
The fawn-hooded (FH) rat is an outbred strain developed
from German brown, albino, and long Evan’s rats.26,27
In 1988, these rats were shown to be hypoxia sensitive,
developing mild PH at sea level and severe PH when
exposed to mild hypoxia.26,27 At Denver altitude, the FH
rat develops PH within a month after birth, and at half
this altitude it develops PH at approximately 20–40 weeks
of life.109,110 On closer investigation, it becomes evident
that the FH rat model is crucial in elucidating certain
aspects of the development of PH with regard to in-
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creased PASMC proliferation, resistance to apoptosis, and
a preference for glycolytic metabolism (known as the War-
burg hypothesis).111 Over the years, many studies done in
this SPI model of PH have allowed us to investigate the
mechanisms underlying these aspects. It is now known
that FH rats have (1) immature developed lungs with a
reduced number of alveoli, (2) an inherited platelet disor-
der characterized by deficient serotonin uptake into plate-
lets, and (3) a chromosome-1 abnormality that disrupts the
mitochondrial reactive oxygen species–hypoxia inducible
factor alpha (HIF-1α)–potassium channel pathway that un-
derlies PH development.26,27,111 Other mechanisms in-
clude downregulation of superoxide dismutase-2 (SOD-2)
and activation of HIF-1α and pyruvate dehydrogenase ki-
nase (PDK).111 Therefore, SOD-2, HIF-1α, and PDK ma-
nipulation may be therapeutic targets, as shown by studies
done in the FH rat model.111 Available data are limited on
therapeutic treatments that have been tested in this model,
with the exception of a few. Fasudil, a Rho-kinase inhibitor
(known to cause vasodilation), has been shown to reduce
severity of PH in the FH rat and to improve lung alveo-
larization and vascularization.112 Another study showed
that vasoactive intestinal peptide (known to cause vasore-
laxation) attenuated PH in the FH rat by suppression of
endothelin and interaction with its receptors.113
Pulmonary artery banding model
Patients with congenital cardiac malformations involving
large left-to-right shunts have a poor prognosis if early
surgery is not performed.114 In 1952, Muller and Dam-
mann115 described a surgical technique called pulmo-
nary artery banding (PAB) as a form of surgical pallia-
tion for patients with such cardiac malformations.116-118
Later, it was noticed that placing the band too distally on
the main pulmonary artery trunk can lead to pulmonary
artery stenosis.118 In 2002, a slight variation of this tech-
nique was used to create the PAB rat model for PH,
which is characterized by progressive pulmonary artery
stenosis and RVH.119,120
During the PAB procedure, a left thoracotomy is per-
formed and the pulmonary artery is dissected away from
the aorta.119,120 An 18-gauge needle is placed alongside
the pulmonary artery, and a silk suture is positioned
around the pulmonary artery to keep the needle in place.
The needle is removed while the suture is tied tightly to
produce a constricted opening in the lumen of the artery,
equal to the diameter of the needle. As the animal grows,
the lumen narrows further, which results in increased RV
afterload.119,120 There are currently no reports on pulmo-
nary vascular remodeling or PH in the PAB model, but
these rats do develop pressure overload–induced RVH.6,77
However, because the pulmonary artery band remains
fixed, it allows researchers to study the molecular events
underlying RV remodeling and test the effects of novel
experimental treatments.121-125
Trichostatin, a broad-spectrum inhibitor of histone
deacetylases, has been shown to worsen RVH and RV sys-
tolic pressure in PAB rats while it did the opposite in left
ventricular hypertrophy.120,126 The divergent effects of the
trichostatin in left ventricular hypertrophy, compared to
those in RVH, highlight the possibility that remodeling of
the RV may, to some extent, differ from that of the left
ventricle. However, this is a poorly investigated aspect of
heart failure research and beyond the scope of this review.
It has been suggested that RV dysfunction in the PAB
model is due to a metabolic shift from glucose oxidation to
glycolysis.123,124 Also, inhibition of the glycolytic enzyme
PDK with dichloroacetate has been shown to improve RV
function and reduce RVH in the PAB model.123,124 The
mechanisms of these improvements are thought to be the
restoration of the RV repolarization and glucose oxida-
tion.123,124 Fang et al.124 tested the efficacy of partial inhibi-
tors of fatty acid oxidation in the PAB model. The authors
were able to show that these inhibitors increased and en-
hanced RV function. Only a few studies have characterized
the PAB model, and more insight into its pathogenesis is
needed. Nevertheless, the PAB model does have a role in
the development of novel treatments that may serve as a
cardioprotective therapy, to be given as complementary
treatment to current PH treatments.4,122,125
Schistosomiasis model
In 2010, Crosby and colleagues127 used the mouse model
of schistosomiasis-induced PH. Schistosomiasis is one of
the most common parasitic infections, together with ma-
laria and ambiasis, with approximately 200–300 million
infected people in more than 70 countries.128-130 Schisto-
somiasis is caused by parasites (flatworm flukes) of the
Trematoda class, such as Schistosoma mansoni.129,130 The
life cycle of the flatworm includes penetration of the skin,
invasion of the intestine, liver, and genito-urinary system,
and release of eggs in the urine or feces of the host, after
which the eggs are secreted into water. The eggs hatch,
and miracidiae infect the freshwater snail to facilitate their
own transformation into cercardiae. The cercardiae persist
in the snail, are released into the water again, and pene-
trate the host’s skin. After penetration, the cercardiae are
transformed into schistosomulae that are transported via
the bloodstream to the lung, where they induce granulo-
mas. A portion of patients with schistosomiasis develop
concurrent progressive pulmonary vasculopathy that is
reminiscent of idiopathic PH.129,130
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In the schistosomiasis model, female C57/BL6 adult
mice received a single injection of a Puerto Rican strain of
S. mansoni that was a suspension of either 75–100 cercar-
iae (for the subacute study) or 30 cercariae (for the chronic
study). Female mice were chosen because they are known
to develop a greater worm burden than males during
chronic infection. In the subacute study, mice killed at 6,
7, or 8 weeks postinfection had a few eggs present in the
lungs and no evidence of pulmonary vascular remodeling.
In the chronic study, mice killed at 7, 12, 17, or 20 weeks
postinfection had a greater lung egg burden and developed
significant pulmonary vascular remodeling. In addition,
plexiform-like lesions were observed in the pulmonary vas-
culature of these mice. However, in this model, no signifi-
cant RVH or PH was observed. This model was then
modified by infecting mice with a suspension of 30 cercar-
iae, which caused RVH and PH after 25 weeks.131
The model was further improved by Graham et al.,132
who infected C57/BL6 mice with S. mansoni cercariae and
intravenously challenged them with S. mansoni eggs. The
infection was done by placing the mice’s tails in a vial con-
taining 30–35 cercariae for 30 minutes.132 Fifty-five days
later, mice were challenged intravenously by injection of
5,000 viable eggs (suspended in 0.5 mL of sterile saline)
into the tail vein. This intravenous challenge mimicked the
deposition of eggs in the lung by collateral shunts, which
normally form in chronically infected mice. This resulted
in pulmonary vascular remodeling and PH, dependent on
the upregulation of interleukin-13.132
A therapeutic drug that has been tested in this model
is praziquantel, a treatment for chronic human schisto-
somiasis.131 Praziquantel increased the permeability of
the parasitic membranes of adult worms to calcium ions,
thereby inducing contraction that resulted in paralysis
and damage of the outer tegumental surface of the adult
worm. Praziquantel treatment (250 mg/kg by oral gavage)
in the S. mansoni mouse model prevented PH and re-
versed pulmonary vascular remodeling. The authors be-
lieve that the underlying mechanism involves clearance
of eggs in pulmonary vasculature and reduction of local
lung cytokine expression.131 This is a very interesting
model that may contribute to further understanding of
underlying mechanisms such as the role of inflammation
in PH associated with schistosomiasis. The model provides
an ideal platform to test novel therapeutic strategies for
schistosomiasis-PH.
BMPR-2 knockout model
A genetic mutation in the BMPR-2 gene has been found
in endothelial cells and PASMCs in the lungs of patients
with familial or idiopathic PH.133,134 The fact that BMPR-
2 plays a crucial role in the development of PH is evi-
dent from the development of PH in BMPR-2-deficient
mice.135,136 In 2004, Beppu and colleagues135,136 developed
a mouse model in which the BMPR-2 mutant allele of the
BMPR-2 gene lacks exons 4 and 5 (which encodes the
transmembrane domain and a portion of the kinase do-
main of BMPR-2). Mice heterozygous for this BMPR-2 mu-
tant allele (BMPR-2+/− ) survive and reproduce normally,
but in PASMCs isolated from these mice, the messen-
ger RNA (mRNA) levels of BMPR-2 are reduced by 50%.
This is associated with a reduced activation of the mole-
cules smad 1, 5, and 8 in response to BMP-2. At base-
line, BMPR-2+/− mice exhibit mild PH with musculariza-
tion and thickening of the pulmonary arteries. Exposure
of these mice to hypoxia (11% FiO2 for 3 weeks) results in
vasoconstriction, muscularization of the small pulmonary
arteries, and increased mPAP.135,136
A major shortcoming in this model is the absence of
RVH and the mildness of the PH.135,136 This shortcom-
ing has been addressed by genetically modifying the mice
to express a dominant negative allele for the BMPR-2
gene in PASMCs.137 These mice develop pulmonary vas-
cular changes resembling the plexiform lesion as well as
PH and RVH.137 Fasudil was tested as therapeutic treat-
ment in this model by Yasuda and colleagues,137,138 who
showed that fasudil treatment (100 mg/kg/day in the
drinking water) alleviates PH. This is a major break-
through, because this study proved Rho-kinase inhibition
to be successful in treating PH associated with a BMPR-2
mutation. The mechanisms by which fasudil alleviates
PH in this model are thought to be independent of the
smad signaling pathway. Furthermore, fasudil has also
been tested and shown to be effective in patients with
PH.139 It is clear that the BMPR-2 knockout model may
play a crucial role in assessing the efficacy of novel experi-
mental treatments that may soon be used in clinical prac-
tice.
Vasoactive intestinal peptide knockout model
In 2007, knockout mice were created by deletion of the
vasoactive intestinal peptide gene (VIP−/− ), on the basis
of the notion that VIP causes pulmonary smooth-muscle
relaxation and either neutralizes or attenuates the actions
of vasoconstrictors such as endothelin.140 VIP expression
is also downregulated in the lungs of patients with PH.140
VIP−/− mice spontaneously develop moderate to severe
PH with pulmonary vascular remodeling, increased mus-
cularization of the pulmonary arteries, and RVH. In-depth
investigation of the molecular mechanisms underlying the
development of PH in VIP−/− mice showed that VIP dele-
tion alters gene expression.141 Altered gene expression in-
Pulmonary Circulation Volume 3 Number 4 December 2013 | 745
cludes (1) underexpression of vasodilator and antiprolif-
erative genes, (2) overexpression of vasoconstrictor and
pulmonary vascular remodeling genes, and (3) upregu-
lation of inflammatory genes.141 Furthermore, VIP sup-
presses tumor necrosis factor-alpha and interleukin-10
and promotes T-regulatory cells, which may indicate an
anti-inflammatory role for VIP.142 However, the exact role
of VIP in PH has not been elucidated, and it should also
be kept in mind that this model differs from human PH
with regard to hemodynamic severity and histology.140
The VIP knockout model has greatly added to our gen-
eral understanding of PH but also supports the concept of
exogenous VIP therapy as therapeutic strategy in PH.143
VIP replacement therapy (500 μg/kg/daily, intraperitone-
ally for 3 weeks) has been shown to reverse PH and correct
gene alterations in the VIP−/− mice.143 Knowledge gained
from this approach has formed the basis for a possible
treatment for humans with PH. This notion is supported
by the fact that the serum concentrations of VIP are de-
creased in patients with PH.144 In a study done by Leuchte
and colleagues,144 20 patients with PH were treated with a
single dose of inhaled aviptadil (a VIP analog, at 100 μg for
15 minutes) before right heart catheterization. Assessment
of the hemodynamic parameters and blood gases displayed
slight improvement of oxygenation with no side effects.144
Further experiments may be needed in order to fully char-
acterize the effects of aviptadil treatment. This model has
been a great help in studying experimental PH.
Endothelin receptor-B knockout model
In 2001, transgenic rats with an endothelin-B (ETB)-
receptor deficiency were created that develop severe PH
with increased mPAP and pulmonary vascular resistance
and diminished cardiac output after exposure to hypobaric
hypoxia (410 mmHg barometric pressure or 76 mmHg
FiO2 for 3 weeks).
145 Endothelin is a peptide with vasoac-
tive properties and the ability to regulate vascular tone
in the normal lung.145 The actions of ET are receptor de-
pendent, with receptors A (ETA) and B (ETB). ETA is ex-
pressed mainly in PASMCs and, if activated, leads to
PASMC proliferation and vasoconstriction. On the other
hand, ETB is expressed in both endothelial cells and
PASMCs. Activation of the endothelial ETB causes vasodi-
latation via the release of nitric oxide and prostaglandin,
while stimulation of the PASMC ETB causes vasoconstric-
tion in the lungs.145 Furthermore, in a model of BMPR-2
mutation it has been shown that, at baseline, these mice
have reduced expression of macrophage-derived ETA and
ETB and that antagonism of ETB results in increased en-
dothelin levels.30 Together these data show that reduced
expression of endothelin receptors increases pulmonary
endothelin levels and thereby contributes to PH.30 It is
also known that in patients with PH, endothelin levels are
increased and receptor expression (ETA and ETB) is
upregulated.146,147 Collectively, the data seem to suggest
that the entire endothelin signaling system (endothelin
and its receptors) plays an important role in PH. The re-
search done in this model has helped in the development
of endothelin receptor antagonists (such as bosentan) as a
safe treatment for PH with significant clinical response.147
Apolipoprotein-E knockout model
In 2011, in a study by Weng and colleagues,148 apolipopro-
tein E–deficient (ApoE−/− ) mice were crossbred with delta-
Glycine-adiponectin mice to generate mice with 3-fold
higher adiponectin serum concentrations. The mice with
higher serum adiponectin levels had reduced PH and pul-
monary vascular remodeling after induction of PH with a
high dose of ovalbumin. The protein ovalbumin induces
pulmonary eosinophilic inflammation in mice character-
ized by pulmonary vascular remodeling similar to that in
humans. ApoE is a vascular protective factor known to
reduce circulating oxidized low-density lipoprotein and
atherogenesis in the vessel wall.149 Furthermore, it has
been reported that patients with PH have increased ApoE
expression and that ApoE deficiency is linked to the devel-
opment of insulin resistance.150,151 In 2007, Hansmann
and colleagues149 reported that ApoE−/− mice spontane-
ously develop PH with increased pulmonary artery muscu-
larization. This is an important finding because it impli-
cates insulin resistance and obesity as risk factors for the
development of PH.149,150 The authors of this particular
study also noticed that the ApoE−/−mice have reduced adipo-
nectin levels.149 Adiponectin is a protein, produced by
the adipose tissue, with beneficial effects in insulin re-
sistance and atherosclerosis.151,152 Subsequently, ApoE-
deficient PASMCs were treated with adiponectin and dis-
played inhibited proliferation.151,152 All of these studies
suggest that adiponectin levels may have a potential ther-
apeutic role as a modulator of pulmonary vascular remod-
eling and vascular tone and may explain the relationship
between insulin resistance/obesity and PH.151,152
Neprilysin knockout model
In 2009, Dempsey et al.153 created neprilysin null (NEP−/− )
mice and exposed them to either normoxia (Denver al-
titude) or hypoxia (18,000 feet, hypobaric chamber) for
a period of 5 weeks. Neprilysin, or neural endopeptidase
(NEP), is a transmembrane metallopeptidase present in
the lung, heart, and peripheral blood vessels.153 In the pul-
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monary vasculature, NEP is expressed in PASMCs, fi-
broblasts, and endothelial cells, with functions including
growth and contraction.153 In lung biopsies from PH pa-
tients, there is an approximately 70% reduction in the
NEP activity, associated with reduced mRNA expression.154
NEP−/− mice developed severe PH characterized by mus-
cularization of the distal pulmonary arteries, thickening of
the proximal media, and adventitia with RVH.153 It was also
shown that a striking increase in PASMC proliferation was
corrected when isolated PASMCs were treated with exoge-
nous NEP (0.01 μg/μL).153 Collectively, these results high-
light the importance of NEP in the pulmonary vascula-
ture and its instrumental role in the pathogenesis of PH,
although this role has not yet been fully elucidated.153-155
Interleukin-6 overexpression model
In 2009, transgenic mice overexpressing lung-specific
interleukin-6 (IL-6) were created by Steiner and col-
leagues.156 IL-6, a pleiotrophic proinflammatory cytokine,
is produced mainly by T cells and macrophages but also
by smooth muscle cells of the tunica media in the vas-
cular wall and adventitia.38,39,156 Aside from its proin-
flammatory action, IL-6 modulates immune processes,
hematopoiesis, and oncogenesis.157,158 In PH research,
elevated levels of IL-6 have been described in both human
PH and animal PH and seem to correlate well with dis-
ease severity and mortality.38,39 Investigators exposed
IL-6-overexpressing mice to CHP (10% FiO2 at sea level
for a period of 3 weeks). They were able to show that
the mice had elevated RV systolic pressure and RVH with
pulmonary vasculopathic changes. Furthermore, the mice
had muscularization of the proximal arterial tree, with pro-
liferative arteriopathy often seen in the distal arteriolar
vessels of PH patients. This suggests that in PH, IL-6 pro-
motes the development and progression of pulmonary vas-
cular remodeling. Authors attributed this action of IL-6 to
its ability to activate signaling pathways that increase endo-
thelial cell proliferation and the expression of anti-apoptotic
proteins.156
Data generated from studies done in the IL-6 overex-
pression model stimulated scientific interest in IL-6 as a
possible therapeutic target in PH and, in general, in the
concept of anti-inflammatory therapies for the treatment
of PH.38,39 In 2010, Furuya et al.157 published a case report
of a female patient with mixed connective-tissue disease
and severe PH. The underlying connective-tissue disease
was treated with tocilizumab, an IL-6 receptor antagonist
(at a dose of 8 mg/kg every 2 weeks for 12 months). The
patient responded well to treatment, with improvement of
functional class (New York Heart Association), 6-minute
walk distance, and hemodynamic parameters on right heart
catheterization (mPAP and pulmonary capillary wedge pres-
sure). The authors did not see any change in cardiac out-
put and pulmonary vascular resistance.157 Similar reports
have been published on the efficacy of pharmacological
IL-6 antagonism in patients with PH as well as its specific
effects on PASMCs isolated from patients with PH.159-161
All of these studies underline the usefulness of the IL-6
overexpression model in studying the function of IL-6 in
the development of PH and the therapeutic potential of
other anti-inflammatory therapies.
Angiopoietin-1 overexpression model
In 2004, Chu et al.162 created a rat model by overex-
pressing angiopoietin-1 (Ang-1). The rationale for the de-
velopment of this model is based on the fact that Ang-1,
a ligand secreted by smooth muscle cells, is essential for
angiogenesis in utero and signals vascular endothelial
cells to stimulate the proliferation of smooth muscle cells
around nascent endothelial tubes.162 Ang-1 is also known
to act synergistically with VEGF to facilitate the matura-
tion of vascular networks in vivo. Chu et al.162 created the
model by injecting 2 1010 genomic particles of adeno-
associated virus-angiopoietin-1 (AAV-Ang-1) into the RV-
outflow tract of rats while using adeno-associated virus-
lacZ (AAV-lacZ)–injected rats and carrier-injected rats
as controls. After 1 or 2 months, the mPAP of Ang-1-
overexpressing rats was significantly increased relative to
that of controls. Increased PASMC proliferation was ob-
served within the medial layer of arterioles, with oblitera-
tion of small vessels, similar to that seen in patients with
PH. Angiograms of the rat lungs displayed blunting of the
small peripheral arterioles that is consistent with severe
PH.162 Ang-1 seems to play a critical role in PH, but re-
ports in the literature seem to be controversial.163-168
Du and colleagues164 have also shown that Ang-1 is
overexpressed in the lung tissue of patients with various
types of PH and that the level of Ang-1 expression is
directly proportional to the severity of the PH. Karapınar
and colleagues166 showed that patients with PH associ-
ated with left heart disease (mitral stenosis) have lower
serum Ang-1 levels than controls. In that study, the au-
thors found a negative correlation between serum Ang-1
levels and severity of PH.166 Kümpers et al.167 published
data showing that patients with idiopathic PH have nearly
3-fold higher plasma levels of Ang-1 than controls. In ad-
dition to these findings, Ang-1 expression remained un-
changed in lungs, PASMCs, and endothelial cells iso-
lated from patients with idiopathic PH.168 Thus, it can be
concluded that Ang-1 plays an important role in angio-
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genesis and vascular remodeling, with the potential to be-
come a therapeutic target in PH.162 However, further stud-
ies are needed for a better understanding of the role of
Ang-1 in PH. A potential angiopoietin therapy would most
probably involve the whole angiopoietin signaling system
(Ang-1, Ang-2, and the endothelium-specific receptor tyro-
sine kinase).
Serotonin transporter overexpression model
In 2004, Maclean and colleagues169 created a transgenic
mouse model by overexpressing the serotonin trans-
porter (5-HTT). In brief, serotonin, also known as 5-
hydroxytryptamine (5-HT), is a potent pulmonary vaso-
constrictor and co-mitogen that is increased in the blood
plasma of patients with PH.169-171 It is synthesized in
endothelial cells of the pulmonary artery by the enzyme
tryptophan hydroxylase-1 and can act on PASMCs and
pulmonary arterial fibroblasts.170-172 Serotonin signaling
occurs via cell surface receptors, and its intracellular lev-
els are modulated by 5-HTT.173 Expression of the 5-HTT
is increased in PASMCs isolated from patients with idio-
pathic PH.169
In the study by Maclean et al.,169 5-HTT-overexpressing
mice were exposed to CHP (10% FiO2 for 28 days) and
developed RVH and pulmonary vascular remodeling. Re-
sults from this model stimulated general interest in the
testing of 5-HTT inhibitors (such as fluoxetine) as thera-
peutic treatment for PH.173 In 2009, Zhu and colleagues174
showed that fluoxetine treatment (10 mg/kg daily by oral
gavage for 4 weeks) prevented PH in the MCT model and
prolonged survival. These are important findings, but se-
rotonin signaling is a complex system (consisting of 5-HT,
5-HT receptors, and 5-HTT), and all its components are
upregulated in patients with PH.171 Many 5-HT receptor
antagonists have now been tested and have shown to be
successful in both cell culture and animal models.171-176
Furthermore, data from Morecroft et al.177,178 suggest that
5-HTT inhibition (LY-393558, a combined 5-HT1B recep-
tor/5-HTT antagonist) may cause pulmonary vasoconstric-
tion, which can be inhibited by simultaneous treatment
with a receptor antagonist. It is also known that compo-
nents of the serotonin signaling system are coregulated by
both 5-HTT and 5-HT receptors.179 Therefore, it is im-
portant for researchers to note that targeting of both the
transporter and the receptor may provide optimal therapy
for PH.179
S100A4/Mts-1 overexpression model
In 1998, Ambartsumian and colleagues180,181 created
transgenic mice by overexpressing S100A4/Mts-1. In
these mice, the S100A4 coding sequences were placed
under control of the mouse mammary tumor virus long
terminal repeat promoter (MMTV LTR).180,181 S100A4/
Mts-1 is a metastasis-promoting protein that forms part of
a family of calcium-binding proteins whose functions in-
clude cell proliferation, differentiation, cytoskeleton dynam-
ics, and apoptosis.180,182 This model was initially created
with the purpose of investigating the role of S100A4/
mts-1 in metastatic mammary cancer.180,181 However, it
was reported that approximately 5% of the S100A4/Mts-1-
overexpressing mice developed pulmonary vascular re-
modeling similar to the plexogenic arteriopathy seen in
humans with PH.182 A reason for using this model to
study PH is that in most animal models, only certain vas-
cular changes (as seen in PH patients) are reproduced,
with a lack of neointimal thickening and plexiform le-
sions.182 These vascular changes are characteristic of se-
vere PH, and in order to study it, researchers began uti-
lizing the S100A4/Mts-1-overexpression mouse model,
which displays these specific vascular changes.182
Unlike male mice overexpressing S100A4/Mts-1, fe-
males developed plexiform lesions.182 S100A4/Mts-1 gene
expression was increased in the lungs of females, com-
pared to those of males, and this was translated as a
greater Mts-1 protein expression in distal pulmonary ar-
teries. In addition, female mice also developed increased
RV systolic pressure, while males remained unaffected.
This same group of researchers isolated PASMCs from
humans with PH, treated them with physiological concen-
trations of 17β-estradiol, and demonstrated an increase in
S100A4/Mts-1 expression. These findings are important
because gender differences are prominent in human idio-
pathic PH, and they may provide a possible explanation
for these differences.183,184
Another important study done in this model involves the
introduction of viral components to the model in order to
establish a link between viral infection and the development
of PH.185 PH is a serious complication of HIV, and in addi-
tion, the involvement of a latent infection with the human
herpes virus-8, also called Kaposi’s sarcoma–associated her-
pes virus, has been prevalent in patients with idiopathic
PH. On the basis of this notion, Spiekerkoetter et al.184
infected 1-year-old S100A4/Mts1-overexpressing mice
with the vasculotrophic virus γHV-68 (murine gamma-
herpesvirus-68). Six months after the γHV-68 infection,
investigators observed perivascular inflammation and oc-
clusive neointimal formation, accompanied by significant
degradation of elastin. They concluded that early viral ac-
cess to the vessel wall may be a key determinant of the se-
verity of vascular pathology following viral reactivation.184
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Furthermore, lung biopsies from children with PH as-
sociated with congenital heart defects showed increased
S100A4/Mts-1 expression in PASMCs of lesions associated
with neointimal formation and plexiform lesions.182
Merklinger and colleagues184,185 investigated the underly-
ing mechanisms for S100A4/Mts-related pulmonary vas-
cular remodeling. In this study, S100A4/Mts-1 mice were
exposed to CHP, lung tissue was analyzed with micro-
array, and a number of genes were shown to be differen-
tially expressed. One of these genes was fibulin-5, a matrix
component necessary for normal elastin fiber assembly.
Fibulin-5 was localized in the pulmonary arteries and asso-
ciated with thickened elastic lamina. This could be an un-
derlying mechanism for the attenuation of pulmonary vas-
cular remodeling in response to elevated pressure.185,186
The S100A4/Mts-1 overexpression model has certainly al-
lowed researchers to investigate a very important part of
the pathogenesis of PH.
CONCLUSIONS
The heterogeneity of PH in humans and the difficulties in
treating it make it a very complex disorder. This has major
implications for the use of animal models and the develop-
ment of improved models. The validity of animal models
has been largely criticized among the clinical and basic-
science community, partly for good reasons. Because of
our limited understanding of PH, the question is often
asked, how can we model a disorder that we do not fully
comprehend? This review has discussed a number of SPI
animal models and highlighted their evolution into im-
proved MPI animal models that more closely correlate
with human PH. The improvement of a particular model
is paramount because an animal model can be called so
only if it effectively models the human disease. If it does,
then it will allow researchers to develop a more clinically
relevant treatment that could potentially improve the qual-
ity of life or prolong the survival of patients with PH and,
if possible, cure PH. Research done with animal models
has vastly contributed to our current understanding of
the pathophysiology of PH, and if we continue to improve
these models, they may help to develop a therapeutic
breakthrough or even a cure. Animal models do not reflect
clinical benefit and cannot be used as a replacement for
clinical trials. A very important point that we want to high-
light is that MPI animal models tend to correlate better
with severe PH in humans than do SPI models. We also
imply that there is a possibility that SPI models may dis-
play features of the early stages of PH in humans that
are often missed because of late diagnosis. Therefore, ani-
mal models can be useful in assessing various stages of
the disease progression. Nonetheless, in our opinion, data
generated from animal models should not be seen as pre-
clinical research, because of the inability to model human
PH with regard to hemodynamic and histological severity.
There is therefore still a long way ahead, but it is gratifying
to see the great progress that has been made in PH re-
search.
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